GLPwatch

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

NCT06716307 · Completed

Last updated 2026-05-28

This study tests how different versions of an injectable medication (CagriSema) affect blood levels of two drugs (cagrilintide and semaglutide) in adults who have overweight or obesity.

Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 18 people
Who can join Ages 18–64 · all sexes
Timeline Started 2024-12 · est. completion 2025-05
Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06716307 ↗

Description as written by the study sponsor.

This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide. It is still being tested in studies and is not yet available for doctors to prescribe. Participants will get an injection with each of the two versions of CagriSema at two different times at the clinic. Like all medicines, the study medicine may have side effects. The study will last for about 18 weeks.

Treatments tested

Main thing measuredAUC0-∞,cagri,0.25 milligram (mg)/0.25mg,SD: Area under the cagrilintide concentration-time curve after a single dose 0.25 mg/0.25 mg CagriSema A in PDS290 pen-injector or CagriSema in DV3384 pen-injector
SponsorNovo Nordisk A/S
Conditions studiedObesity
GLP-1 drugs semaglutide, cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06716307 ↗